Telephone
61.3.9093.3855
Address
North Melbourne Suite 401 55 Flemington Road Melbourne, Victoria (VIC) 3051
Description
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 14.42 - 31.97
Trade Value (12mth)
AU$7,940,102.00
1 week
-5.01%
1 month
2.96%
YTD
13.8%
1 year
84.94%
All time high
31.97
EPS 3 yr Growth
-152.80%
EBITDA Margin
11.50%
Operating Cashflow
$43m
Free Cash Flow Return
6.70%
ROIC
7.70%
Interest Coverage
4.20
Quick Ratio
2.70
Shares on Issue (Fully Dilluted)
355m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
4.32
Date | Announcements |
---|---|
01 May 25 |
App 3Z Final Director Interests - A Whitaker
×
App 3Z Final Director Interests - A Whitaker |
29 April 25 |
Anne Whitaker Board Resignation
×
Anne Whitaker Board Resignation |
28 April 25 |
Telix Provides Regulatory Update on TLX101-CDx
×
Telix Provides Regulatory Update on TLX101-CDx |
24 April 25 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
22 April 25 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
22 April 25 |
Telix Reports US$186M Q1 Revenue, Up 62% YOY
×
Telix Reports US$186M Q1 Revenue, Up 62% YOY |
17 April 25 |
Telix Notice of AGM, Proxy Form and Online Guide
×
Telix Notice of AGM, Proxy Form and Online Guide |
16 April 25 |
IPAX-Linz Promising Efficacy for TLX101 Glioma Tx Candidate
×
IPAX-Linz Promising Efficacy for TLX101 Glioma Tx Candidate |
14 April 25 |
Change of Registry Address Notification
×
Change of Registry Address Notification |
07 April 25 |
Telix Responds to Recent U.S. Government Actions
×
Telix Responds to Recent U.S. Government Actions |
04 April 25 |
Anne Whitaker Appointed as Non-Executive Director
×
Anne Whitaker Appointed as Non-Executive Director |
04 April 25 |
App 3X Initial Director Interests - A Whitaker
×
App 3X Initial Director Interests - A Whitaker |
03 April 25 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
03 April 25 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
03 April 25 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
03 April 25 |
Notification of cessation of securities - TLX
×
Notification of cessation of securities - TLX |
02 April 25 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
02 April 25 |
Change in substantial holding
×
Change in substantial holding |
25 March 25 |
Pending Release of Shares from Voluntary Escrow
×
Pending Release of Shares from Voluntary Escrow |
21 March 25 |
FDA Approves New Prostate Cancer Imaging Agent Gozellix
×
FDA Approves New Prostate Cancer Imaging Agent Gozellix |
21 March 25 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
18 March 25 |
Illuccix Approved in Brazil - 1st PSMA-PET Approval in LATAM
×
Illuccix Approved in Brazil - 1st PSMA-PET Approval in LATAM |
17 March 25 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
17 March 25 |
Cleansing Notice
×
Cleansing Notice |
17 March 25 |
Application for quotation of securities - TLX
×
Application for quotation of securities - TLX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.